SEALX - Online request for information for physicians

Please find below additional information about the study for the participants: 

The study consists of applying an investigational topical gel twice daily for 8 weeks. You will be given either the ALX-101 Gel 5% drug or a placebo. This study treatment is experimental, and you will have 50% chance of receiving the placebo. This is a blinded study, so you and the study doctor will not know which treatment you are receiving.

Photographs of your atopic dermatitis will be taken throughout the study.

This study will last a period of up to 3 months and includes 6 visits. Visits take approximately 1 to 2 hours each, except for the screening visit which may take up to 3 hours.

Study participants will be compensated up to 450$


If you are interested in this study for your patients, please click Next below and answer the required questions.

A note on privacy
This survey is anonymous.
The record of your survey responses does not contain any identifying information about you, unless a specific survey question explicitly asked for it. If you used an identifying token to access this survey, please rest assured that this token will not be stored together with your responses. It is managed in a separate database and will only be updated to indicate whether you did (or did not) complete this survey. There is no way of matching identification tokens with survey responses.